Bicycle Therapeutics (BCYC) Q1 2026 earnings summary

Executive summary

• Report covers the quarter ended March 31, 2026, for a clinical-stage pharmaceutical company focused on oncology using proprietary Bicycle® molecules.

• Strategic reprioritization in March 2026 shifted focus to next-generation therapeutics, including nuzefatide and radiotherapeutics, and included a 30% workforce reduction and program discontinuations, expected to reduce annual operating expenses by ~50%.

• No products approved for sale; revenue is from collaborations, which declined due to terminations with Genentech and Novartis.

• Presented promising clinical and preclinical data for nuzefatide pevedotin in EphA2-expressing cancers, including pancreatic cancer, and zelenectide pevedotin in metastatic urothelial cancer.

• Cash runway extended into 2030 due to operational savings and reduced expenses.

Financial highlights

• Collaboration revenue was $0.9M for Q1 2026, down from $10.0M year-over-year, reflecting terminated partnerships.

• Net loss was $60.8M, or $(0.87) per share, nearly flat compared to the same quarter last year.

• Research and development expenses decreased to $48.9M from $59.1M year-over-year, mainly due to lower zelenectide pevedotin program costs, reduced share-based compensation, and workforce reduction.

• General and administrative expenses fell to $17.5M from $21.1M year-over-year.

• Cash and cash equivalents were $559.5M as of March 31, 2026, down from $628.1M at year-end 2025.

Outlook and guidance

• Cash runway expected to fund operations for at least 12 months from the filing date and is now projected to extend into 2030 due to cost-saving initiatives.

• Near-term expenses and capital requirements are expected to decrease due to cost-saving initiatives and portfolio reprioritization.

• Focused on advancing nuzefatide in pancreatic cancer, expanding the radiotherapeutics pipeline, and evaluating regulatory pathways for zelenectide pevedotin in metastatic urothelial cancer.

• Initial dose selection data from the Duravelo-2 trial to be presented at the 2026 ASCO Annual Meeting.

• Long-term expenses may increase if clinical development and commercialization efforts expand.